Results 41 to 50 of about 9,220 (202)

Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation

Scientific Reports, 2022
Glycolytic and mitochondrial oxidative metabolism, which are two major energy sources in tumors, are potential targets in cancer treatment. Metabolic reprogramming from glycolysis to mitochondrial oxidative metabolism and vice versa is an adaptive ...
Gang Cheng, M. Hardy, M. You, B. Kalyanaraman   +3 more
semanticscholar   +1 more source

Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia

Malaria Journal, 2006
Background Atovaquone is part of the antimalarial drug combination atovaquone-proguanil (Malarone®) and inhibits the cytochrome bc1 complex of the electron transport chain in Plasmodium spp.
Kremsner Peter G, Hailu Asrat, Gebru Tamirat, Kun Jürgen FJ, Grobusch Martin P   +4 more
doaj   +1 more source

Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil

Parasite, 2005
The efficacy of atovaquone and sulfadiazine was examined alone or in combination for the treatment of mice infected with six Brazilian Toxoplasma gondii strains previously genotyped using the PCR-RFLP assays of the SAG2 gene, in addition to RH strain ...
Alves C.F., Vitor R.W.A.
doaj   +1 more source

Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells

International Journal of Molecular Sciences, 2021
A major contributing factor in triple-negative breast cancer progression is its ability to evade immune surveillance. One mechanism for this immunosuppression is through ribosomal protein S19 (RPS19), which facilitates myeloid-derived suppressor cells ...
N. Gupta, S. Gaikwad, Itishree Kaushik, S. Wright, M. Markiewski, S. Srivastava   +5 more
semanticscholar   +1 more source

Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo

Malaria Journal, 2020
Background The drug combination atovaquone–proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone–proguanil treatment failures have been reported.
Laurencie Massamba, Marylin Madamet, Nicolas Benoit, Alicia Chevalier, Isabelle Fonta, Véronique Mondain, Pierre-Yves Jeandel, Rémy Amalvict, Pascal Delaunay, Joel Mosnier, Pierre Marty, Christelle Pomares, Bruno Pradines   +12 more
doaj   +1 more source

Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models

Physics and Imaging in Radiation Oncology, 2021
Background and purpose: Tumor hypoxia is an important cause of radioresistance and is associated with poor outcome.SPECT (Single-photon emission computed tomography) imaging enables visualizing tumor characteristics. We investigated the SPECT-radiotracer
Fokko J. Huizing, Bianca A.W. Hoeben, Jasper Lok, Otto C. Boerman, Sandra Heskamp, Johan Bussink   +5 more
doaj   +1 more source

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria

Cochrane Database of Systematic Reviews, 2021
Background The World Health Organization (WHO) in 2015 stated atovaquone‐proguanil can be used in travellers, and is an option in malaria‐endemic areas in combination with artesunate, as an alternative treatment where first‐line artemisinin‐based ...
A. Blanshard, P. Hine
semanticscholar   +1 more source

In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand

Malaria Journal, 2008
Background The emergence of Plasmodium falciparum resistant to most currently used antimalarial drugs is the major problem in malaria control along the Thai-Myanmar and Thai-Cambodia borders.
Mungthin Mathirut, Tan-ariya Peerapan, Khositnithikul Rommanee   +2 more
doaj   +1 more source

Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern

ACS Infectious Diseases, 2021
The antimicrobial medication malarone (atovaquone/proguanil) is used as a fixed-dose combination for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers.
Madalina E. Carter-Timofte, R. Arulanandam, N. Kurmasheva, K. Fu, G. Laroche, Zaid Taha, D. van der Horst, Léna Cassin, Renée M. Van der Sluis, Enrico Palermo, D. Di Carlo, D. Jacobs, Glib Maznyi, Taha Azad, R. Singaravelu, Fanghui Ren, A. L. Hansen, M. Idorn, C. Holm, M. Jakobsen, J. van Grevenynghe, J. Hiscott, S. Paludan, J. Bell, J. Seguin, L. Sabourin, M. Côté, J. Diallo, Tommy Alain, D. Olagnier   +29 more
semanticscholar   +1 more source

Hair concentrations of anti-malarials in returned travellers-the HAIR study: Proof of principle analysis

Travel Medicine and Infectious Disease, 2023
Background: Hair analysis to identify substance use is an established methodology. This could also be a method to monitor adherence to antimalarial drugs.
Regula Steiner, Anne Kaulich, Daniel Müller, Patricia Schlagenhauf   +3 more
doaj   +1 more source